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Obesity,themostcommonnutritionaldisorderinindustrializedcountries,isassociatedwithanincreasedmortalityandmorbidity
of cardiovascular disease (CVD). Obesity is primarily considered to be a disorder of energy balance, and it has recently been
suggested that some forms of obesity are associated with chronic low-grade inﬂammation. The present paper focuses on the
current status of our knowledge regarding chronic inﬂammation, a link between obesity and CVDs, including heart diseases,
vascular disease and atherosclerosis. The paper discusses the methods of body fat evaluation in humans, the endocrinology and
distribution of adipose tissue in the genders, the pathophysiology of obesity, the relationship among obesity, inﬂammation, and
CVD, and the adipose tissue-derived cytokines known to aﬀect inﬂammation. Due to space limitations, this paper focuses on C-
reactive protein, serum amyloid A, leptin, adiponectin, resistin, visfatin, chemerin, omentin, vaspin, apelin, and retinol binding
protein 4 as adipokines.
1.Introduction
Obesity, the most common nutritional disorder in industri-
alized countries, is associated with an increased mortality
and morbidity of cardiovascular disease (CVD) [1]. The
World Health Organization estimates that more than 1
billion adults worldwide are overweight, 300 million of
whom are clinically obese—deﬁned as having a body mass
index (BMI) equal to or greater than 30kgm−2,o ra
waist circumference greater than 94cm for men and 80cm
for women [2]. Obesity is a chronic, multifactorial, and
complex disease resulting from a long-term positive energy
balance, in which both genetic and environmental factors are
involved [3, 4]. It was recently suggested that some forms of
obesity are associated with chronic low-grade inﬂammation
[5].
CVDs, including heart disease, vascular disease and
atherosclerosis, are the most critical global health threat,
contributing to more than one-third of the global mor-
bidity. In most cases, these clinical conditions result from
atherosclerosis, which was once identiﬁed as a lipid-storage
disease. At the present time, CVD is recognized as a chronic
inﬂammatory condition of the vessel wall that results from
the transendothelial passage (transcytosis) of cholesterol-
rich atherogenic Apo-B lipoproteins (VLDL, IDL and LDL)
from the plasma into the intima. These lipoproteins are
retained in the subendothelial space, which leads to inﬁl-
tration of macrophages and T cells that ultimately then
interact with each other and with the cells of the arterial
wall [6, 7]. It is likely that inﬂammation induced by obesity
accelerates the atherosclerosis. Adipose tissue is recognized
as an important player in obesity-mediated CVD. In 1994,
adipose tissue was ﬁrst identiﬁed as the source of the
hormone leptin, opening the door for a new era of research
that focused on adipocyte endocrinology [8]. It is now
apparent that adipocytes have a more complex physiological
role [9]. Adipocytes produce large numbers of hormones,
peptides, and other molecules that aﬀect cardiovascular
function, not only in an endocrine manner, but also by
autocrine and paracrine mechanisms [10]. This might lead
to cytokine-mediated inﬂammatory, changes in the liver,
systemic inﬂammation and atherosclerosis.2 Mediators of Inﬂammation
This paper focuses on the inﬂammation related to
obesity and CVD. It will discuss the methods of body fat
evaluation in humans, the endocrinology and distribution
of adipose tissue in the genders, the pathophysiology of
obesity, the relationship among obesity, inﬂammation and
CVD, and the adipose tissue-derived cytokines known to
aﬀect inﬂammation.
2.MethodsofEvaluationofBodyFatinHumans
There are many methods that can be used to evaluate body
fatindiﬀerentpopulations[2,11,12].Whileanthropometric
measurements of weight-for-height have been traditionally
used to evaluate obesity, more recently, BMI has become
a standard parameter. BMI is deﬁned as weight in kilo-
grams divided by height in square meters. The normal
range is 19–24.9kg/m2, with overweight deﬁned as 25–
29.9kg/m2, and obesity as ≥30kg/m2. BMI is not always a
reliable measurement of body composition in individuals,
particularly in older and younger people. Unfortunately,
BMI does not provide any insight into regional body fat
distribution. Thus, simple anthropometric measurements,
such as waist circumference, can also be used to determine
the valid index of visceral fat accumulation, in addition to
being able to serve as an indicator of health risks associated
with visceral obesity. A waist circumference of greater than
102cm in men and 88cm in women is a risk factor for
CVD. A particularly important anthropometric parameter
that has been increasingly applied in recent years is sagittal
abdominal diameter (SAD) [13]. Using a simple caliper
that was originally developed by Kahn, this anthropometric
indicator can measure visceral fat tissue alone [14].
With regard to other techniques, one of the ﬁrst that
shouldbeconsideredisthemeasuringofbodydensity,asthis
provides information on the relationship between the body
mass and volume. With tetrapolar bioelectric impedance
analysis, data is obtained by measuring the resistance of
the body exposed to the impact of an alternating current
of 50kHz at a strength of 800μA. Radioisotopic techniques
use deuterium or tritium as markers to measure the total
body liquid and total body potassium. Infrared spectrometry
is a simple but not particularly reliable method, based on
the application of two sources of monochromatic light.
Ultrasonographic measuring of fat tissue is currently the
favored technique by which one can measure both the
subcutaneous and visceral fat tissues. Measurements are
carried out using a 7.5- and 3.5-mHz transducer for the
subcutaneous and visceral fat tissue, respectively. The most
accurate method for measuring central obesity is through
the use of magnetic resonance imaging or computer-assisted
tomographic scanning. Unfortunately, these approaches are
too expensive for routine use.
3. Endocrinology andDistribution of
Adipose Tissuebetween Genders
It is now apparent that adipose tissue is not simply
a storage reservoir of fat, but is an active endocrine
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Figure 1: Cytokines secreted by adipocytes and/or macrophages in
human adipose tissue.
organ that plays multiple roles in the body. Adipose
tissue contributes to the inﬂammatory process in obese
subjects in both vascular and nonvascular tissues [15].
Abnormal levels of metabolites, such as lipids, fatty acids
and, cytokines from adipose tissue, activate monocytes
and increase the secretion of inﬂammatory cytokines.
Adipose tissue from obese individuals contains activated
macrophages that together with adipocytes produce various
cytokines (Figure 1). These include inﬂammation-related
adipokines such as leptin, adiponectin, tumor necrosis
factor alpha (TNF-α), interleukin-1 (IL-1), interleukin-6
(IL-6), procoagulant substances such as PAI-1, vasoactive
substances such as leptin, angiotensinogen and endothelin,
and molecules that may contribute to insulin resistance
such FFA, TNF-α and resistin. IL-1 signaling involves the
type I Interleukin 1 receptor (IL-1R/IL-1R1), a Toll-like
receptor that heterodimerizes with the IL-1R accessory
protein (IL-1RAcP). Interleukin 1 receptor antagonist (IL-
1Ra) is an anti-inﬂammatory cytokine that binds to IL-
1R in competition with the proinﬂammatory cytokine IL-
1. The relative occupancy of the IL-1R1-IL-1RAcP receptor
complex with IL-1 agonist or with IL-1Ra determines
whether the inﬂammatory signaling is “on” or “silenced”,
respectively. IL-1β induction of IL-6 and prostaglandin
E2 (PGE2) signaling is indicated in Figure 3. In obesity,
these cytokines are released into the circulation by adipose
tissue, stimulating hepatic CRP production. Levels of the
prothrombotic molecule PAI-1 are also increased, whereas
adiponectin, which is produced exclusively by adipocytes, is
decreased in obesity. One of the key vasoactive substances
produced by adipocytes is leptin, which is an important
regulator of food intake. Other adipocyte-derived molecules,
includingprostaglandins,adiponectin,andthemorerecently
discovered resistin, aﬀect metabolic function and might play
a role in causing cardiovascular end-organ damage.
Serum adipokine levels are elevated in humans and
animals with excess adiposity. Visceral fat appears to pro-
duce several adipokines more actively than subcutaneous
adipose tissue, and an increased abdominal adiposity in
the visceral depot renders these individuals more prone
to metabolic and cardiovascular problems [16]. HealthMediators of Inﬂammation 3
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Figure 2: Mechanism of the relationship between inﬂammation induced by obesity and cardiovascular disease. Gray box shows the
traditional cardiovascular disease (CVD) risk factors. The arrow and plus symbols indicate the enhanced courses. Smoking, obesity,
hypertension, diabetes, physical inactivity and hypercholesterolemia are established risk factors of CVD. In obese individuals, macrophages
ﬁrstaccumulate withintheadiposetissue,leadingtolocalinﬂammation.Astheobesityincreases,severalproinﬂammatoryfactors,including
IL-1, IL-6 and TNF-α, are produced in the adipose tissue. Macrophage accumulation and the subsequent local inﬂammation are believed
to result in numerous metabolic dysfunctions that typically accompany obesity, including systemic inﬂammation. Endothelial dysfunction
occurs during the early stages of atherosclerosis and is responsible for the pathophysiological changes in subclinical atherosclerosis, which
include changes in a variety of mediators, surface proteins, and in autacoids that are involved in vasomotion, coagulation and inﬂammation.
Obesity also can increase systemic oxidative stress independently of blood glucose and diabetes. One of the major events of atherosclerosis is
CVD.
problems associated with obesity are generally related more
to the central (abdominal, visceral) distribution of fat rather
than to the amount of fat, and the distribution of fat
diﬀers between males and females [17, 18]. Men exhibit a
more central accumulation of fat, whereas women exhibit a
more gluteal/femoral accumulation. The original deﬁnition
ofobesityformales(androidtype)andfemales(gynoidtype)
datestotheﬁrstclinicalobservationsmadebyVaguein1947.
The greatest health risk is associated with fat distribution in
the central or upper body (android) parts. Recent research
[19, 20] has shown that sex hormones play an important role
in obesity and that there are diﬀerences in the occurrence of
insulinresistanceandheartdiseasesthataredependentupon
gender.Findingshaveindicatedthatboththetotalamountof
fat that an individual carries and the distribution of that fat
are important. At present, it is diﬃcult to accurately measure
fat in the body, and there is currently no simple method
available for routine clinical use.
Epidemiological and clinical evidence strongly suggests
a major role for sex steroid hormones in the regulation of
adipose tissue distribution. Sex steroid hormones, such as
estrogen, progesterone, and androgen, are involved in the
metabolism, accumulation, and distribution of adipose tis-
sues.Normaldistributionofbodyfatoccurswhensexsteroid
hormones are present. If a decrease in sex steroid hormones
occurs, such as that seen during aging or gonadectomy,
there is a greater tendency for obesity states, in addition to
increases in major risk factors for CVD.
4. Mechanismsof the Relationship among
Obesity,Inﬂammation, andCVD
4.1. Systemic Inﬂammation. As individuals become obese
and their adipocytes enlarge, the adipose tissue undergoes
molecular and cellular alterations that subsequently aﬀect
systemicmetabolism(Figure 2).First,macrophagesaccumu-
latewithinadiposetissue,leadingtolocalinﬂammation.Sev-
eral proinﬂammatory factors are produced in adipose tissue
as obesity increases. When compared to lean individuals,
adipose tissue in obese individuals shows higher expression
of proinﬂammatory proteins, including TNF-α and IL-
6[ 21, 22]. Macrophage numbers in adipose tissue also
increase with obesity [23], apparently acting as scavengers4 Mediators of Inﬂammation
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Figure 3: Interleukin-1β (IL-1β) induction of interleukin-6 (IL-6) and prostaglandin E2 (PGE2) signaling. IL-1β binds to the IL-1R1/IL-
1R1AcP heterodimer, which then initiates the signaling cascade that causes the translocation of the transcription factor nuclear factor-κB
(NF-κB) into the nucleus, where it induces the transcription of pro- and anti-inﬂammatory genes including inducible nitric oxide synthetase
(iNOS),IL-6,IL-1Raandcyclooxygenase-2(COX-2).COX-2catalysestheconversionofarachidonicacid(AA)toprostaglandinH2(PGH2).
PGH2 is converted into PGE2 by terminal PGE synthase (PGES). PGE2 signals occur via four diﬀerent G-protein coupled receptors, EP1R-
EP4R, each of which has multiple splice variants with diﬀerent signaling properties.
of apoptotic adipocytes. It also has been reported that there
is a marked increase in these scavengers in obese subjects
[24]. Macrophage accumulation and the subsequent local
inﬂammation are believed to result in numerous metabolic
dysfunctions that accompany obesity, including systemic
inﬂammation and atherosclerosis.
Visceral fat secretes more cytokines than subcutaneous
adipose tissue [16]. A recent study elegantly demonstrated
that transplantation of visceral adipose tissue from gene-
tically obese mice into Apoe-deﬁcient mice increased athero-
sclerosis in the recipient animals, suggesting that inﬂamed
adipose tissue exerts distinct vascular eﬀects, presumably
through inﬂammatory cells such as macrophages within the
visceral adipose tissue [25]. Macrophages within visceral
adipose tissue are known to express and release cytokines.
These cytokines reach the liver though the portal circulation,
where they can stimulate hepatic inﬂammation [26], thereby
inducing a chronic systemic inﬂammatory response.
4.2. Endothelial Dysfunction. Clinical and experimental data
support a link between systemic inﬂammation and endothe-
lial dysfunction. Mounting evidence shows that disturbed
endothelial function may be an early marker of an ongoing
atherosclerotic process. Thus, endothelial dysfunction has
increasingly been recognized to play an important role in a
number of conditions associated with a high prevalence of
atherosclerotic CVD. Inﬂammatory cytokines are important
protagonists in the formation of atherosclerotic plaques,
eliciting eﬀects throughout the atherosclerotic vessel. Impor-
tantly, the development of atherosclerotic lesions, regardless
of risk factors (e.g., diabetes, hypertension, obesity), is
characterized by the disruption of the normal function of
endothelial cells.
The reasons for coronary endothelial dysfunction are
complex and may involve ischemia/reperfusion injury.
Smoking, obesity, hypertension, diabetes, physical inactivity,
and hypercholesterolemia are established atherogenic risk
factors. Endothelial dysfunction is regarded as an early
stage of atherosclerosis, which is a chronic inﬂammatory
disease [27]. Chronic inﬂammation is a major contributing
factor to atherosclerosis and various markers of inﬂam-
mation, ﬁbrinolysis, and coagulation are upregulated in
patients with established atherosclerotic disease. For vascular
homeostasis, endothelial cells are of the utmost importance
and they produce a variety of mediators, surface proteins,
and autacoids involved in vasomotion, coagulation, and
inﬂammation. Adipose tissue expresses enzymes involved in
theangiotensinsystem(RAS)(renin,angiotensin-converting
enzyme (ACE)), as well as the nonrenin-angiotensin system
(NRAS) (cathepsin D, cathepsin G, tonin, chymase) [28].
TheidentiﬁcationofelevatedCRPasatransientindependent
risk factor for endothelial dysfunction might provide an
important clue for linking a systemic marker of inﬂam-
mation to the progression of atherosclerotic disease. Thus,
CRP has been proposed for risk assessment of CVD in
the at-risk general population. Available evidence suggests
that low-grade inﬂammation is accompanied by decreasedMediators of Inﬂammation 5
bioavailability of endogenous NO and that TNF-α may play
a key role in these events. The adipose tissue constitutes
a source of other vasoactive factors, such as leptin, serum
amyloid A (SAA), or apelin, among others [29]. Since
blood vessels express receptors for most of the adipocyte-
derived factors, adipose tissue seems to play a key role in
cardiovascular physiology via the existence of a network of
local and systemic signals. Therefore, these data demonstrate
that markers of inﬂammation have independent predictive
value for clinical and subclinical CVD beyond that of the
traditional risk factors.
4.3. Subclinical Atherosclerosis and CVD. The development
of atherosclerosis in obesity stems from a constellation of
interrelated proatherogenic mechanisms. It is well estab-
lished that a higher BMI is associated with subclinical
inﬂammation, as reﬂected by increased CRP levels [30],
and increased systemic oxidative stress that is indepen-
dent of blood glucose and diabetes [31]. Recent evidence
has suggested that leptin stimulates cholesterol uptake by
macrophages, particularly in the presence of high glu-
cose. This then triggers the formation of foam cells and
the development of atheromatic lesions. Obesity-related
hypoadiponectinemia might also contribute to impaired
endothelialfunction,increasedvascularROSproductionand
overall proatherogenic eﬀects [32]. Finally, increased release
of proinﬂammatory cytokines by adipose tissues, including
IL-6, IL-1, and TNF-α, sustains vascular wall inﬂammation
and promotes pro-atherogenic gene expression [33].
There is interest in identifying markers of subclinical
atherosclerosis, such as coronary artery calcium (CAC) and
carotid intimal medial thickness (CIMT), in order to facil-
itate an earlier diagnosis and possible prevention of CVD.
CRPlevelswerefoundtobecorrelatedwithCIMTinagroup
of young subjects [34], but not in older individuals [35]. In
other studies, levels of IL-6 have been shown to be associated
with the amount of CAC [36], and the CD40 ligand, which
is a marker of enhanced innate immunity, has been found
to be correlated with CIMT in human subjects [37]. Since
leptin levels have been shown to be associated with CAC
independently of body weight measures or other risk factors,
this points to a possible proatherogenic role for leptin [38].
5. Adipose Tissue-DerivedCytokines
Known to Affect Inﬂammation
5.1. CRP. Of the many positive and negative acute-phase
reactants, perhaps the most recognized is CRP, which is a
member of the pentraxin family that attaches to the plasma
membrane of damaged cells causing cell death through
activation of the complement cascade [39]. More than 20
prospective epidemiologic studies have demonstrated that
high-sensitivity CRP is an independent predictor of myocar-
dialinfarction,stroke,peripheralarterialdisease,andsudden
cardiacdeath,eveninapparentlyhealthyindividuals[40,41].
Clearly, CRP is one of the strongest markers of chronic
inﬂammation, and it has been reported that it also directly
participates in the coronary and aortic atherosclerosis that
leads to cardiac events [42].
Ouchi et al. [43] conﬁrmed CRP mRNA expression
in human adipose tissue using quantitative real-time poly-
merase chain reaction. In the same article, the authors
proposed that adipose tissue is an important source of
circulating CRP. However, they made no attempt to inves-
tigate the stimuli able to induce CRP. Esposito et al.
[44] investigated the eﬀects of weight loss and lifestyle
changes on vascular inﬂammatory markers in obese women.
After 2 years, they found that BMI, as well as the serum
concentrations of IL-6, IL-18, and CRP, decreased more in
the intervention group than in the control subjects, whereas
the adiponectin levels signiﬁcantly increased. The beneﬁcial
eﬀects of a Mediterranean-style diet on endothelial function
and vascular inﬂammatory markers have been documented
in patients with metabolic syndrome. When compared
to patients consuming a control diet, patients consuming
a Mediterranean-style diet have signiﬁcantly lower serum
concentrations of high-sensitivity CRP, IL-6, IL-7, and IL-18
as well as a decreased insulin resistance [45]. In a quartile
analysis of the percent weight reduction, the largest weight
reduction quartile did not show signiﬁcant decreases in the
CRP levels, whereas the middle quartiles showed remarkable
CRP decreases. Based on inﬂammatory status, there may
be an optimal pace of exercise combined with weight loss
[46]. Two recent studies have demonstrated that exercise
training in conjunction with weight reduction signiﬁcantly
aﬀected the CRP levels, body composition, and human left
ventricular growth [47, 48].
5.2. Serum Amyloid A (SAA). Serum amyloid A (SAA), an
important marker of inﬂammation, is an apolipoprotein
that is mainly synthesized in mammalian liver [49]. Human
SAA is a 12.5-kDa protein whose levels can increase up to
1,000- fold in the serum 24–36h after infection or injury,
decline after 4–5 days, and then return to baseline after
10–14 days [50]. The human genome encompasses four SAA
genes, of which three encode functional proteins. SAA1 and
SAA2 are highly homologous reactants whose concentration
can increase upon infection, trauma, and obesity [51, 52],
whereas SAA3 is a pseudogene and SAA4 is a constitutively
expressed minor constituent of the nonacute-phase HDL
[53].
SAA has proven to be a suitable and sensitive indicator of
the various stages of inﬂammation involved in inﬂammatory
disorders. SAA is comparable to CRP, as both are major
acute phase proteins that can increase up to 1,000-fold and
reach 1mg/mL in the serum under stimulation [50]. They
can be produced by the liver under inﬂammatory stimuli,
and their eﬀects are mediated through pro-inﬂammatory
cytokines (IL-1 and TNF-α) and “messenger” cytokines (IL-
6) [54]. However, in contrast to CRP, which is mainly
expressed in the human liver, SAA is expressed in both the
liverandadipose tissue.SAAisnowacceptedasanadipokine
that is produced by adipocytes and which directly mediates
obesity-associated inﬂammation. Hence, SAA might serve as
a better indicator of obesity and obesity-associated diseases,6 Mediators of Inﬂammation
especiallywhenvasculardiseasesandmetabolicdisordersare
present.
SAA is known to be a marker for obesity, as its expression
is well correlated with obesity [55]. Some studies have
shown that SAA levels are positively associated with BMI
levels and that weight loss led to decreased SAA levels. In
1999, Danesh et al. [56] ﬁrst reported that concentrations
of SAA protein were strongly correlated with obesity. Since
then, more than ten studies have shown that SAA is
strongly associated with obesity [57–59]. In addition, it
has been shown that SAA gene expression is increased in
the adipose tissue of obese subjects and is signiﬁcantly
correlated with adipocyte size and inﬂammatory biomarkers
[52].
Recent studies have shown that SAA elevation can
predict cardiovascular events analogously with or even better
than CRP by itself [60–62] and in this sense, it has been
speculated that SAA might be one of the links or even a
proatherogenic risk factor between inﬂammation and CVD
[63, 64] .S A Ai sa b l et ob o t ha l t e rv a s c u l a rp r o t e o g l y c a n si n
a proatherogenic manner [65] and stimulate the production
of various inﬂammatory mediators in cultured vascular
endothelial cells, neutrophils, and monocytes [66]. Endothe-
lial cells, smooth muscle cells, monocytes, and macrophages
in atherosclerotic lesions have been reported to account
for the extrahepatic production of SAA, as the presence of
both SAA mRNA and protein products have been detected
in these cell types [67]. SAA has also been accepted as
being a biomarker of cerebrovascular disease and carotid
artery intima-media thickness, which is an early index
of atherosclerosis [68–71]. However, a very recent study
indicated that SAA does not mediate early atherosclerosis
[57].
SAA has also been found to be associated with metabolic
disorders, such as diabetes, insulin resistance, and metabolic
syndrome [72, 73]. Additionally, genes critical for insulin
sensitivitywerealsofoundtobedownregulatedinadipocytes
treated with recombinant SAA [74].
5.3. Leptin. Leptin, which was the ﬁrst adipocyte hormone
identiﬁed, inﬂuences food intake through direct eﬀects on
the hypothalamus [75]. The adipocyte-derived hormone
leptin has actions in the brain (e.g., hypothalamus, cortex
and limbic areas) and in a number of peripheral tissues as
well (e.g., cells of the pancreas, liver and immune system).
However, the central action of leptin in the brain, and in
particular the hypothalamus, has been best characterized
with regards to energy homeostasis and its importance
for reproductive functions [76]. Moreover, disruption of
peripheral leptin signaling in mice has been shown to cause
no signiﬁcant changes in either the energy balance or glucose
homeostasis [77].
Mice lacking the gene coding for leptin (named ob/ob
mice) are obese and diabetic. When ob/ob mice are treated
with regular injections of leptin, they show reduced food
intake, increased metabolic rate, and weight loss [78].
These eﬀects appear to be mediated mainly by the central
nervous system, as intracerebroventricular injection of leptin
produces signiﬁcant eﬀects at much lower doses than those
required by systemic injection. Systemic injections of leptin
have a beneﬁcial eﬀect in children with congenital leptin
deﬁciencies [79]. In a pioneering study, administration of
exogenous leptin to individuals with lipoatrophic diabetes
resulted in marked reductions in triacylglycerol concentra-
tions, liver volume, and glycated hemoglobin. Ultimately,
this treatment resulted in the discontinuation of or large
reductions in the patient’s antidiabetic therapy [80]. Unfor-
tunately, leptin concentrations are already high in most
obese individuals because of the increased amount of leptin-
secreting adipose tissue [81]. In these individuals, increasing
the leptin concentrations only induces the target cells to
become resistant to actions of the hormone. Therefore,
further studies need to be undertaken to clarify potential
therapeutic strategies using leptin in these types of patients.
Leptinisinvolvedinthecontrolofnotonlyenergyhome-
ostasis but also immunity. During fasting/starvation, when
plasma leptin levels decline, neural pathways in the hypotha-
lamus cause the appetite to increase and energy expenditure
to decrease as the body attempts to restore its fat stores
[82]. In addition, the fall in plasma leptin diminishes thyroid
hormoneproductionandinhibitsthereproductiveaxis,both
of which help to save energy during nutritionally lean times
[83]. These metabolic eﬀects of leptin are in part centrally
mediated by activation of the hypothalamic-sympathetic
nervous system axis [84]. In addition to the complete leptin
deﬁciency disorder, relative leptin deﬁciency is an emerging
clinical syndrome that is now being seen more often in
several clinical conditions, including congential or acquired
lipodystrophy as well as exercise-induced energy deﬁciency
and hypothalamic amenorrhea or anorexia nervosa. Leptin
replacement therapy might prove to be a therapeutic option
for patients with these disorders [85]. Very recently, admin-
istration of chemical chaperones that decrease ER stress also
restored leptin sensitivity in diet-induced obese mice [86].
In obese subjects who have lost weight, modiﬁcations that
lead to decreased energy expenditure may predispose the
individual to regain the weight. However, when subjects are
administered “replacement” doses of leptin that restore their
circulating leptin concentrations to preweight-loss levels,
the weight gain can be prevented [87]. This suggests that
the weight-reduced state is a condition of relative leptin
deﬁciency. Recent reports have shown that in addition
to its action on the hypothalamus, leptin may also act
on the cortex and limbic areas, which are involved in
cognitive and emotional regulation of feeding behavior [88].
Teleologically, the adaptations mediated by reduced leptin
may have evolved as a protection against the threat of star-
vation by limiting energy use and enhancing energy storage
[89].
The potential eﬀects of leptin in the pathophysiology of
cardiovascular complications of obesity remain diverse [90].
While some studies [91, 92] have indicated that circulating
leptin levels are not signiﬁcantly related to the risk of CVD
or mortality in a diabetic population, these studies did ﬁnd
that leptin was associated with obesity and inﬂammatory
markers. Even so, other reports have suggested that leptin
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[93]. Therefore, this protein may elevate the blood pressure
by stimulating the autonomic nervous system. Leptin has
been found to have multiple eﬀects on the cells of the artery
wall. In human vascular endothelial cells, leptin upregulates
the expression of the plasminogen activator inhibitor-1
[94], and leptin also helps modulate ACAT1 expression
and cholesterol eﬄux from human macrophages [95]. In
addition, leptin has been reported to increase nitric oxide
(NO) bioavailability in blood vessels via the activation of
endothelial NO synthase (eNOS) [96] and inducible NO
synthase (iNOS) [97] in the endothelial and smooth muscle
cells, respectively. Recent studies that measured coronary
artery disease have demonstrated that hyperleptinemia
was associated with coronary atherosclerosis [98, 99], with
the association determined to be independent of insulin
resistance. Other studies have shown that leptin may have a
role in neointimal formation in response to arterial injury
[100, 101]. In fact, very obese, leptin-deﬁcient mice have
been found to be protected from atherosclerosis despite all
of the metabolic risk factors, suggesting that this hormone
may directly contribute to the risk of vascular disease [102].
Moreover, in a prospective study in humans in which
anthropometric and metabolic risk factors were controlled,
the circulating leptin concentrations were shown to be an
independent risk factor for predicting cardiovascular events
[103]. Therefore, when chronically elevated concentrations
of leptin are seen in obese individuals, this may indicate
a predisposition to progression of atherosclerosis in these
individuals.
5.4.Adiponectin. Adiponectinisaproductofadipocytes,and
i t sl e v e l si nh u m a n sd e c r e a s ei no b e s es u b j e c t s[ 104]. As one
ofthemostextensivelystudiedadipokines, adiponectinhas3
diﬀerent oligomers, each of which may have a diﬀerent bio-
logical function [105]. The major receptors for adiponectin
are AdipoR1 and AdipoR2. These belong to a new family of
receptors that are predicted to contain seven transmembrane
domains but which will be structurally and functionally
distinctfromtheG-proteincoupledreceptors.Arecentstudy
has shown that AdipoR2 stimulates energy dissipation by
increasing fatty acid oxidation while inhibiting oxidative
stress and inﬂammation [106, 107]. Adipocytes secrete high
levels of adiponectin that then exert anti-inﬂammatory
eﬀects, most notably in atherosclerotic plaques [108]. These
eﬀectsoccurduetothesuppressionofTNF-αandproinﬂam-
matory cytokines such as IL-6 and interferon-c, along with
the induction of other anti-inﬂammatory factors such as
the IL-1 receptor antagonist [109]. In contrast, adiponectin
levels have been shown to be low in several diﬀerent forms
of insulin resistance. In vivo, adiponectin enhances energy
consumptionandfattyacidoxidationintheliverandmuscle,
which reduces the tissue triglyceride content, thereby further
enhancing the insulin sensitivity [110]. In adiponectin trans-
genic mice, there is improvement of the lipid proﬁle [111,
112],andwhenplasmatriglyceridesarereduced,thisleadsto
an increased VLDL catabolism in the skeletal muscle [113].
Taken together with its metabolic and anti-inﬂammatory
eﬀects, it has been proposed that adiponectin not only
contributes to the beneﬁcial eﬀects of body weight loss but
also has a role in modulating the cardiovascular system.
As might be expected based on the above observa-
tions, adiponectin promotes an antiatherogenic and anti-
inﬂammatory program of gene expression and function in
the vessel wall. Adiponectin downregulates the expression
of adhesion molecules on the endothelial cells and directly
improves endothelial dysfunction [114, 115]. Adiponectin
also reduces proliferation in a receptor-independent fashion
in the vascular smooth muscle cells [116]. In a very recent
study, it has been shown that adiponectin reduces lipid
accumulation, down-regulates the expression of scavenger
receptors in macrophages, and promotes macrophage polar-
ization, all of which play a role in anti-inﬂammatory
activities [117]. Other studies have also indicated that
adiponectin has an important role in cardiovascular protec-
tion. Hypoadiponectinemia is found in patients with angio-
graphically demonstrated coronary artery disease [118]. In
obesechildren,ithasbeenreportedthatreducedadiponectin
concentrations are of more importance than conventional
cardiovascular risk factors, and that this inﬂammation status
is related to early atherosclerosis [119]. However, in a large
prospective study that was combined with a meta-analysis
of previously published prospective studies, the adiponectin
levels at baseline were found to be rather weak predictors
of CVD risk [120]. However, other studies have shown that
adiponectin exerts beneﬁcial eﬀects at nearly all stages of the
atherogenesis process [121], and that the adiponectin levels
are inversely correlated to the progression of the coronary
artery calcium in both diabetic and nondiabetic subjects
[122]. Serum total and high-molecular weight adiponectin
are also associated with biomarkers of inﬂammation, insulin
resistance, and endothelial function, all of which are inde-
pendent risk factors of CVD [123].
5.5. Resistin. Resistin, which is one of the most recently
identiﬁed adipokines, has been proposed to be an inﬂam-
matory marker for atherosclerosis. While it has been shown
to induce increases in CRP production by the macrophages
[124], resistin is an example of the new adipokines that
appear to have contrasting roles when examined in mice versus
humans. For example, conﬁrmation of the results found
in mice has proven to be diﬃcult in human populations.
This may be due to the fact that resistin appears to be
derived from diﬀerent sources in humans as compared to
rodents. This protein was initially shown to be released
in large amounts from mouse adipocytes, with obese mice
having elevated levels that were accompanied by insulin
resistance [125]. However, investigations in humans suggest
that resistin is expressed in adipocytes with monocytes and
macrophages [126, 127]. This lack of homology between
the human and mouse resistin genes suggests a potential
divergence in function [128]. Since macrophages are known
inﬂammatory modulators, resistin may be an inﬂammatory
marker in humans. Supporting this possible inﬂamma-
tory role in humans are results that show recombinant
resistin activates human endothelial cells, as measured by an
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molecules and chemokines, while simultaneously increasing
the CD40-ligand signaling by down-regulating the tumor
necrosis factor receptor-associated factor-3 [129]. Moreover,
Calabro et al. [130] has shown that resistin can promote
human coronary artery smooth muscle cell proliferation by
activation of the extracellular signal-regulated kinase 1/2
(ERK) and phosphatidylinositol 3-kinase (PI3 K) pathways.
Taken together, these ﬁndings suggest a possible mechanistic
link between resistin and cardiovascular disease via proin-
ﬂammatory pathways.
In addition, there have been many recent reports that
support a role for resistin in obese rodent models. Resistin
has been found to modulate nutritional regulation and may
possibly play a role in maintaining fasting blood glucose
levels [131]. Further rodent studies have also suggested that
resistin mRNA levels are higher in abdominal fat depots,
as compared to deposits in the thigh [132], and that these
serum resistin levels are positively correlated with BMI
[133]. Recent investigations in humans have shown there are
higher serum resistin levels in obese subjects as compared
to lean subjects. These higher levels were also positively
correlated with changes in the BMI and the visceral fat
area [134, 135]. Lee et al. [136] found higher circulating
resistin levels in obese mice when compared to their lean
counterparts. Additional studies have reported signiﬁcant
reductions in circulating resistin levels following moderate
weight loss [137] and postgastric bypass [138]. Collectively,
these observations suggest that resistin may indirectly be
involved in the nutritional regulation in humans.
5.6.Visfatin. Visfatin, alsoknown as nicotinamide phospho-
ribosyltransferase (NAMPT), which was previously known
as a pre-B cell colony-enhancing factor (PBEF), functions as
a growth factor for early B cells within the immune system
[139]. Fukuhara et al. [140] demonstrated that visfatin
is a secreted protein that is expressed and regulated by
the adipose tissue. As compared to subcutaneous adipose
tissue, there are greater amounts of visfatin within visceral
fat depots. Furthermore, this study indicated that visfatin
could bind to and activate insulin receptors, similar to that
seen for insulin both in vivo and in vitro. However, this
eﬀect of visfatin is controversial. For example, Revollo et
al. were unable to reproduce the insulin-mimetic activity
of this protein, even though a signiﬁcant physiological
role in the regulation of beta-cell function through the
NAD biosynthetic activity was detected. Thus, the authors
suggested that NAMPT could play an important role in
the control of glucose metabolism [141]. After these novel
ﬁndings, Fukuhara et al. decided to retract their previously
published paper [142].
Thevisfatinpeptidewasoriginallydiscoveredintheliver,
skeletal muscle, and bone marrow and found to act as a
growth factor for B-lymphocyte precursors. This peptide is
not only produced by white adipose tissue (WAT), but also
by endotoxin-challenged neutrophils, and is able to prevent
apoptosis via a mechanism mediated by caspases 3 and 8
[143]. Circulating visfatin levels are closely correlated with
WAT accumulation and visfatin mRNA levels increase in the
course of adipocyte diﬀerentiation. Visfatin expression is up-
regulated by IL-6 and TNF-α, and is down-regulated by GH
[144]. Insulin has no eﬀect on visfatin mRNA [145]. More-
over, visfatin is up-regulated by the peroxisomal proliferator-
activated receptor (PPAR)-alpha and PPAR-gamma agonists
in obese rats. Since it has been shown to be associated with
improved glycemic control and lipid proﬁles, this suggests
that PPAR-alpha and PPAR-gamma agonists may act, at least
in part, via the up-regulation of visfatin expression [146].
In addition to inducing chemotaxis and the production of
IL-1, TNF-α, IL-6, and costimulatory molecules by CD14C
monocytes, visfatin also increases their ability to induce
alloproliferative responses in lymphocytes, eﬀects which are
mediated intracellularly by p38 and MEK1 [144].
Possible associations between circulating visfatin and
anthropometric or metabolic parameters in obesity and type
2 diabetes have been found in some but not all reported
studies [147–149]. These contradictory ﬁndings may be
due in part to the considerable diﬀerences found in the
visfatin immunoassays [150]. In human studies, it has been
shown there is a positive correlation between the visceral
adipose tissue visfatin gene expression and BMI, along with
a negative correlation between BMI and subcutaneous fat
visfatin [151]. This suggests that visfatin regulation varies
within diﬀerent depots and that the adipose depot ratios
are highly dependent upon the obesity of the subjects. A
wide population study in humans has recently discovered
a direct correlation between plasma visfatin and the BMI
and body fat content in males only. This study failed to ﬁnd
any diﬀerences in the expression between the visceral and
subcutaneous fat depots [152].
Several studies have shown that there are diﬀerent disor-
ders that exhibit altered plasma levels of this protein [153–
156]. Thus, visfatin plasma concentrations may potentially
be related to lipid metabolism [157] and the inﬂammatory
response [158]. Since an increased expression of this protein
has been observed in the macrophages of unstable carotid
and coronary atherosclerosis in humans [159], and there is
a negative association between the visfatin plasma levels of
visfatin and vascular endothelial function [160], it has been
proposed that visfatin plays a role in plaque destabilization.
NAMPT, which was originally identiﬁed as PBEF, has been
shown to act as a cytokine independent of its enzymatic
activity, and thus plays a major part in regulating immune
responses [161]. Since NAMPT has been implicated in
the pathogenesis of several acute or chronic inﬂammatory
conditions, such as atherosclerosis and CVD [161], it may
act as a pro-inﬂammatory cytokine and potentially have a
beneﬁcial eﬀect on insulin secretion.
At the present time, the role of visfatin in the modulation
of glucose metabolism, as well as its ability to bind to the
insulin receptor is still under debate [162–164]. As a number
of inconsistencies among the diﬀerent visfatin studies exist,
the role of this adipokine in obesity and insulin resistance
has yet to be clearly deﬁned.
5.7. Chemerin. Recently, chemerin (retinoic acid receptor
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highly expressed in adipose tissue and liver [165]. Chemerin
is an agonist of the orphan G-protein coupled receptor
chemokine-like receptor 1 (CMKLR1, ChemR23) [166] that
is expressed by cells of the innate immune system [167].
Therefore, chemerin might be further evidence of a link
between obesity and inﬂammation. Chemerin is secreted as
an inactive precursor, and then activated through proteolytic
cleavage by serine proteases of the coagulation, ﬁbrinolytic
and inﬂammatory cascades. Chemerin appears to be a novel
and promising adipokine, and in several recent studies,
human chemerin plasma levels have been shown to have
a signiﬁcant association with the BMI, inﬂammation, and
metabolic syndrome [168–170].
Platelets have been found to be a rich cellular source
of chemerin. In some pathological conditions, chemerin is
activated and then released, which leads to the elevation
of blood chemerin levels [171]. Recent studies have shown
that both adipocytes [172] and ﬁbroblast cells [173]c a n
produce chemerin. Chemerin has also been measured in
a number of human inﬂammatory exudates, including
ascitic ﬂuids from human ovary cancer and liver cancer,
as well as synovial ﬂuids from arthritic patients [174].
Angiotensin-converting enzyme (ACE) may be responsible
for the activation of prochemerin. If so, as has been shown
in vitro, this eﬀect should be able to be blocked by an ACE
inhibitor such as captopril [175]. However, further studies
will be necessary to clarify this potential mechanism in
vivo. There is also growing evidence that the bioactivity of
chemeriniscloselyregulatedbyproteolyticcleavageintheC-
terminal region, which may control its maximal chemotactic
oranti-inﬂammatoryeﬀects[176].Whiletheprimaryamino
acid sequences indicate that chemerin is structurally distinct
from the CXC and CC chemokines, it functions exactly
like a chemokine and can induce leukocyte migration and
intracellular calcium mobilization. Chemerin also exerts
potent anti-inﬂammatory eﬀects on activated macrophages,
which express the chemerin receptor CMKLR1 (chemokine-
like receptor-1) in a cysteine protease-dependent manner
[177].
Chemerin is a newly described adipokine with eﬀects
on adipocyte diﬀerentiation and metabolism in vitro [165].
In rodents, there is conﬂicting data with regard to the
association of chemerin with obesity and diabetes. While
thereisadecreasedchemerinexpressionintheadiposetissue
of db/db mice as compared with controls [178], chemerin
expression is signiﬁcantly higher in the adipose tissue of
impaired glucose tolerant and diabetic Psammomys obesus
as compared with normal glucose-tolerant sand rats [179].
It has also been demonstrated that chemerin or chemerin
receptor knockdown impairs the diﬀerentiation of 3T3-L1
cells into adipocytes, reduces the expression of adipocyte
genes involved in glucose and lipid homeostasis, including
adiponectin and leptin, and alters the metabolic functions
in mature adipocytes [170]. In humans, no signiﬁcant
diﬀerences were noted for the chemerin levels between
subjects with type 2 diabetes and normal controls. However,
in normal glucose-tolerant subjects, chemerin levels were
signiﬁcantly associated with BMI, triglycerides, and blood
pressure [179]. Plasma chemerin levels in normal subjects
are also signiﬁcantly associated with BMI, circulating triglyc-
erides, and blood pressure, suggesting a strong relationship
of this protein with obesity-associated complications [179].
It is possible that visceral fat may potentially contribute
to the chronic inﬂammation that is observed in obese
individuals. However, only a few studies have investigated
the adipokine concentrations in the portal circulation [180].
In order to be able to determine the physiological role
of chemerin in the glucose metabolism, and to identify
c h e m e r i n ’ st a r g e tt i s s u e sa sw e l la sr e l e v a n ts i g n a lt r a n s d u c -
tion pathways, further studies will need to be undertaken.
5.8. Omentin, Apelin, Vaspin, and Retinol-Binding Protein
4( R B P 4 ) .Omentin, which was originally referred to as
intelectin and ﬁrst found in the intestinal Paneth cells, has a
predicted molecular weight of 33kDa [181]. Omentin is a fat
depot-speciﬁc secretory protein synthesized by the visceral
stromal vascular cells, but not the adipocytes. It has also
been found in the human lung, intestine, and heart [182]
and is strongly expressed in the human ovaries and placenta
[183]. This new adipokine is codiﬁed by two genes (1 and 2)
and is highly and selectively expressed in the visceral adipose
tissue. In obesity, omentin 1 plasma levels and the adipose
tissue gene expression are decreased, and there is a positive
correlation with the plasma adiponectin and high-density
lipoprotein. These levels were negatively correlated with
waist circumference, BMI, and insulin resistance [184, 185].
Administration of glucose and insulin to human omental
adipose tissue explants resulted in a dose-dependent reduc-
tion of the omentin-1 expression. Furthermore, prolonged
insulin-glucose infusion in healthy individuals resulted
in signiﬁcantly decreased plasma omentin-1 levels [186].
Recombinant omentin enhances the uptake of glucose in
isolated adipocytes and dramatically increases the insulin
induction of Akt/PKB phosphorylation [182]. However,
further studies need to be undertaken, as the physiological
role of omentin in glucose metabolism along with omentin’s
target tissues, receptor, and the relevant signal transduction
pathways have yet to be determined.
Apelin is a bioactive peptide that is produced by
adipocytes, vascular stromal cells, the heart, and the car-
diovascular system [187]. In humans, both obesity and
insulin signiﬁcantly elevate the plasma levels of apelin and
this peptide appears to act as a circulating and paracrine
hormone [187]. The gene that encodes the apelin, receptor
shares the greatest sequence identity with the angiotensin
A T 1r e c e p t o r[ 187]. In experimental animal models of heart
failure, the cardiac apelin system is down-regulated by
angiotensin II, while restoration is achieved after treatment
with an angiotensin type 1 receptor blocker [188]. In the
cardiovascular tissues of rats, apelin production is up-
regulated by hypoxia [189] and ischemic cardiomyopathy
[190], which perhaps may be a compensatory mechanism.
In spontaneously hypertensive rats, exercise training has also
been shown to up-regulate the apelin production [191].
Apelin has a positive hemodynamic eﬀect, as it acts an
inotrope in both normal and failing rat hearts and in
isolated cardiomyocytes [192, 193]. Apelin may be able to10 Mediators of Inﬂammation
regulate insulin resistance by facilitating the expression of
brown adipose tissue uncoupling proteins and by altering
adiponectin levels [194]. Decreased plasma apelin levels have
been observed in patients with lone atrial ﬁbrillation [195]
and chronic heart failure [196]. Cardiac resynchronization
therapy has been used to treat these patients successfully,
with increases in the apelin levels observed after initiation of
the therapy [197].
Vaspin is a member of the serine protease inhibitor
family. This adipocytokine has been isolated from the
visceral adipose tissue of Otsuka Long-Evans Tokushima
Fatty (OLETF) rats that are at an age when the body
weight and hyperinsulinemia has peaked [198]. OLETF
rats are commonly used as a model of human type 2
diabetes. This model also shares common components of the
human metabolic syndrome, including abdominal obesity,
insulin resistance, hypertension, and dyslipidemia [199].
Vaspin production decreased at the same time the diabetes
worsened and body weight fell in the untreated OLETF rats.
However, when the animals were treated with insulin or
pioglitazone, serum vaspin levels were maintained [198].
This suggests that the up-regulation of vaspin may have a
defensive action against insulin resistance. Human vaspin
mRNA has been reported to be expressed in the visceral
and subcutaneous adipose tissue. In addition, it has been
shown to be regulated in a fat-depot speciﬁc manner, and
to be associated with obesity and parameters of insulin
resistance [200, 201]. It has also been reported that elevated
vaspin serum concentrations are correlated with obesity and
impaired insulin sensitivity, whereas type 2 diabetes appears
to abrogate this correlation [202, 203]. Vaspin expression
decreases in conjunction with a worsening of the diabetes
and a body weight loss. These studies indicated that vaspin
might play a causative role in the development of obesity
and metabolic disorders or, at least, be a biomarker for
thesediseases.Inordertoclarifythesepotentialmechanisms,
further investigation using more sophisticated methods will
need to be undertaken.
Using the adipose-speciﬁc Glut4 knockout (adipose-
Glut4(−/−)) mice model, retinol-binding protein 4 (RBP4)
has been identiﬁed as a highly expressed circulating
adipokine that causes insulin resistance when it is overex-
pressed or injected into mice [204]. In the circulation, RBP4
isboundtotransthyretin,whichcausesdecreasesintheRBP4
renal clearance. In ob/ob mice, there was a 4-fold increase in
transthyretin plasma levels as compared to lean mice or diet-
induced obese mice [205]. A large number of subsequent
studiesconﬁrmedtherewasanassociationbetween increases
inthecirculatingRBP4levelsandvariousaspectsofadiposity
[206], insulin resistance [207, 208] ,d i a b e t e sm e l l i t u s[ 209],
and metabolic syndrome [210, 211]. However, there are
also other studies that have been unable to establish these
associations [212, 213]. The reason for this discrepancy may
be explained in part by the diﬀerent methods that were used
tomeasuretheRBP4andthediﬀerentpopulationsemployed
in these various studies. In some very recent studies, it
has been reported that increased plasma RBP4 levels are
associated with inﬂammatory cardiomyopathy [214]a n d
cerebral infarction [215]. Therefore, at the current time,
whether RBP4 functions as an adipokine in humans and
exerts metabolic eﬀects on glucose metabolism remains
uncertain.Furtherstudieswillneedtobeperformedin order
to clarify RBP4’s exact role in humans.
6. Conclusions
The worldwide incidence of obesity has markedly increased
during recent decades. Obesity and associated disorders now
constitute a serious threat to the current and future health
of all populations on earth. Obesity represents a major
risk factor for diseases including CVD,,atherosclerosis and
diabetes, in which inﬂammation acts as a major driver in the
pathogenesis. Both adipocytes and macrophages within fat
tissue secrete numerous cytokines that may contribute to the
characteristic pathophysiological changes. By expanding our
knowledge on inﬂammation and the link between obesity
and CVD, this should make it possible to improve our
understanding of the pathophysiology of obesity.
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